SYMBOL:

    Up to 100 tickers separated by a space
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
DYAX
(NQNM:DYAX Last Sale: 4.99 )
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (DYAX : $4.99)
$319 million Market Cap at September 12, 2013
Employs 145.
Biomedics SubIndustry up .00% / Health Industry up .00% Today
300 Technology Square Research Report Earnings Snapshot - Last 10/28/18
Cambridge, MA 02139 Fact Sheet
Phone: (617) 225-2500 Financial Statements
Fax: (617) 225-2501 Peer Comparison
Annual Reports

Henry E. Blair, Chmn./CEO, Stephen S. Galliker, CFO
Developed and patented phage display technology with applications in the discovery and development of new therapeutic, separations, diagnostic and industrial enzyme products. IPO at $15 August 14, 2000. Raised $60 million, selling 4 million shares, 22% of the outstanding. Lead Manager: J.P. Morgan. Secondary sold 5.5 million shares at $5.65 March 9, 2006.
Historical Charts    Technical Analysis
No Historical Data available for DYAX

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common DYAX $4.99 $ 0 $4.89 $5.03 689,288 $2.24 $5.1799 63,837
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10121
Common Stock $318,547

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2024 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex